TDP1 and adenocarcinoma: Against the adenocarcinoma cells, the conjugation is either detrimental, with an activity lower than that of both parent compounds, when 4 is the anti-TDP1 candidate, or neutral, with regard to the activity of the less active agent (6), when 5 is the anti-TDP1 candidate.